 |
|
The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis
Hau Liu, MD, MBA, MPH;
Kaleb Michaud, MS;
Smita Nayak, MD;
David B. Karpf, MD;
Douglas K. Owens, MS, MD;
Alan M. Garber, MD, PhD
Arch Intern Med. 2006;166:1209-1217.
Background Teriparatide is a promising new agent for the treatment of osteoporosis.
Methods The objective of this study was to evaluate the cost-effectiveness of teriparatide-based strategies compared with alendronate sodium for the first-line treatment of high-risk osteoporotic women. We developed a microsimulation with a societal perspective. Key data sources include the Study of Osteoporotic Fractures, the Fracture Intervention Trial, and the Fracture Prevention Trial. We evaluated postmenopausal white women with low bone density and prevalent vertebral fracture. The interventions were usual care (UC) (calcium or vitamin D supplementation) compared with 3 strategies: 5 years of alendronate therapy, 2 years of teriparatide therapy, and 2 years of teriparatide therapy followed by 5 years of alendronate therapy (sequential teriparatide/alendronate). The main outcome measure was cost per quality-adjusted life-year (QALY).
Results For the base-case analysis, the cost of alendronate treatment was $11 600 per QALY compared with UC. The cost of sequential teriparatide/alendronate therapy was $156 500 per QALY compared with alendronate. Teriparatide treatment alone was more expensive and produced a smaller increase in QALYs than alendronate. For sensitivity analysis, teriparatide alone was less cost-effective than alendronate even if its efficacy lasted 15 years after treatment cessation. Sequential teriparatide/alendronate therapy was less cost-effective than alendronate even if fractures were eliminated during the alendronate phase, although its cost-effectiveness was less than $50 000 per QALY if the price of teriparatide decreased 60%, if used in elderly women with T scores of –4.0 or less, or if 6 months of teriparatide therapy had comparable efficacy to 2 years of treatment.
Conclusions Alendronate compares favorably to interventions accepted as cost-effective. Therapy with teriparatide alone is more expensive and produces a smaller increase in QALYs than therapy with alendronate. Sequential teriparatide/alendronate therapy appear expensive but could become more cost-effective with reductions in teriparatide price, with restriction to use in exceptionally high-risk women, or if short courses of treatment have comparable efficacy to that observed in clinical trials.
Author Affiliations: Division of Endocrinology and Metabolism (Drs Liu and Karpf) and Center for Primary Care and Outcomes Research (Drs Liu, Nayak, Owens, and Garber and Mr Michaud), Stanford University, Stanford, Calif; and Department of Medicine, VA Palo Alto Health Care System, Palo Alto, Calif (Drs Nayak, Owens, and Garber).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cost-Effectiveness of Different Screening Strategies for Osteoporosis in Postmenopausal Women
Nayak et al.
ANN INTERN MED 2011;155:751-761.
ABSTRACT
| FULL TEXT
Dynamic Microsimulation Models for Health Outcomes: A Review
Rutter et al.
Med Decis Making 2011;31:10-18.
ABSTRACT
| FULL TEXT
Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling
Black et al.
J. Clin. Endocrinol. Metab. 2008;93:2166-2172.
ABSTRACT
| FULL TEXT
Teriparatide in the treatment of osteoporosis
Stroup et al.
Am J Health Syst Pharm 2008;65:532-539.
ABSTRACT
| FULL TEXT
|
